The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
Autor John Geigerten Limba Engleză Paperback – 23 aug 2016
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (3) | 698.41 lei 38-44 zile | |
| Springer Nature Switzerland – 16 iun 2024 | 698.41 lei 38-44 zile | |
| Springer – 23 aug 2016 | 1310.97 lei 6-8 săpt. | |
| Springer Us – 24 sep 2012 | 1393.26 lei 6-8 săpt. | |
| Hardback (3) | 1122.42 lei 6-8 săpt. | |
| Springer Nature Switzerland – 16 iun 2023 | 1122.42 lei 6-8 săpt. | |
| Springer Us – 30 dec 2003 | 1402.61 lei 6-8 săpt. | |
| Springer – 7 mai 2013 | 1816.83 lei 6-8 săpt. |
Preț: 1310.97 lei
Preț vechi: 1598.74 lei
-18% Nou
Puncte Express: 1966
Preț estimativ în valută:
250.97€ • 258.11$ • 208.20£
250.97€ • 258.11$ • 208.20£
Carte tipărită la comandă
Livrare economică 19 februarie-05 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781493943999
ISBN-10: 1493943995
Pagini: 368
Ilustrații: XXIX, 338 p. 24 illus., 17 illus. in color.
Dimensiuni: 178 x 254 x 19 mm
Greutate: 6.9 kg
Ediția:Softcover reprint of the original 2nd ed. 2013
Editura: Springer
Colecția Springer
Locul publicării:New York, NY, United States
ISBN-10: 1493943995
Pagini: 368
Ilustrații: XXIX, 338 p. 24 illus., 17 illus. in color.
Dimensiuni: 178 x 254 x 19 mm
Greutate: 6.9 kg
Ediția:Softcover reprint of the original 2nd ed. 2013
Editura: Springer
Colecția Springer
Locul publicării:New York, NY, United States
V-ar putea interesa
-
-10%Preț: 265.32 lei295.14 lei -
Disaster LawKristian Cedervall Lauta-18%Preț: 1035.38 lei1262.67 lei -
-14%Preț: 714.18 lei830.45 lei -
Health Inspector, Eh?Peter K. P. LeePreț: 123.31 lei -
Nanotechnology in DermatologyAdnan Nasir-5%Preț: 1088.02 lei1145.29 lei -
Biointeractions of NanomaterialsVijaykumar B. Sutariya-25%Preț: 997.11 lei1334.83 lei -
FDA Review of Drug ApplicationsMorris Cooperman-27%Preț: 472.52 lei647.69 lei -
Cell Phone Use & Health RisksCynthia Kempson-27%Preț: 546.62 lei747.52 lei -
Non-Biological Complex Drugs: The Science and the Regulatory LandscapeDaan J.A. Crommelin-15%Preț: 647.05 lei761.24 lei -
Regulatory ToxicologyFranz-Xaver Reichl-5%Preț: 3366.91 lei3544.12 lei -
Springer Handbook of Marine BiotechnologySe-Kwon Kim-18%Preț: 1977.01 lei2410.99 lei -
Chirurgie und RechtUlrich Eickhoff-5%Preț: 361.43 lei380.46 lei -
Das urologische GutachtenKarl-Horst Bichler-5%Preț: 783.47 lei824.70 lei -
-5%Preț: 444.31 lei467.69 lei -
-15%Preț: 475.67 lei559.62 lei -
-5%Preț: 385.69 lei405.98 lei -
-5%Preț: 381.16 lei401.23 lei -
-5%Preț: 383.49 lei403.67 lei -
Sicherheit von Medizingeräten: Recht - Risiko - ChancenNorbert Leitgeb-5%Preț: 521.57 lei549.01 lei -
Principles of Safety PharmacologyMichael K. Pugsley-18%Preț: 1211.46 lei1477.39 lei -
The Ethics of Terminal Care: Orchestrating the End of LifeErich E.H. LoewyPreț: 379.93 lei
Cuprins
Complexity of Biologica CMC Regulation.- Biologics are Not Chemical Drugs.- An Effective CMC Strategy is Possible.- Challenge of Adventitious Agent Control.- Source Materials for Biologics.- Manufacture of the Biologic API.- The Biologic Final Product Process.- Complex Process-Related Impurities.- Molecular Structural Analysis.- Functional Activity (Potency).- Setting Specifications and Expiry Dates.- Demonstrating Product Comparability.- CMC-Focused Regulatory Meetings.- References.
Notă biografică
John Geigert is President of BioPharmaceutical Quality Solutions, which specializes in providing CMC regulatory strategy consulting for the biopharmaceutical and biologic industry. Dr. Geigert has over 35 years of CMC industrial experience and leadership in the biopharmaceutical industry. Dr. Geigert has served on the PDA Board of Directors, co-chaired the PDA Biotech Advisory Board and served as an expert member of the USP Biotechnology Committee. Dr. Geigert has written extensively for the Regulatory Affairs Professional Society (RAPS) Focus (What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products (Aug-Nov 2009, 4-part series) and Demystifying CMC Regulatory Strategy (Sept 2011-Mar 2012, 4-part series)).
Textul de pe ultima copertă
An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities – the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in the last several years. So much has changed since the 1st edition of this book was published in 2004. There are now additional manufacturing processes for producing commercial biopharmaceuticals – transgenic plant cell cultures and transgenic animals. In addition to commercial recombinant proteins and monoclonal antibodies, there are now commercial cell-based medicines (cellular therapy) and DNA-based medicines (gene therapy). Biosimilars are now on the marketplace in Europe, and under review for commercial approval in the USA. Vaccine manufacturing has resurged due to the concerns of potentially pandemic mutated animal influenzas (e.g., swine flu, bird flu). Strategic international regulatory guidances have been adopted that are driving the entire pharmaceutical industry, including biopharmaceuticals, to a higher standard of performance, including Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality Systems (PQS). The vast majority of the over 600 regulatory references listed in this book were either issued or updated since the release of the 1st edition. All of these changes are the reason this updated edition includes not only biopharmaceuticals but also other biologics (e.g., live virus vaccines, human plasma-derived proteins, cell-based medicines, natural-sourced proteins) that have CMC regulatory compliance concerns and challenges in common with the genetically-engineered biologics (i.e., the biopharmaceuticals).
About The Author
John Geigert is President of BioPharmaceutical Quality Solutions, which specializes in providing CMC regulatory strategy consulting for the biopharmaceutical and biologic industry. Dr. Geigert has over 35 years of CMC industrial experience and leadership in the biopharmaceutical industry. Dr. Geigert has served on the PDA Board of Directors, co-chaired the PDA Biotech Advisory Board and served as an expert member of the USP Biotechnology Committee. Dr. Geigert has written extensively for the Regulatory Affairs Professional Society (RAPS) Focus (What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products (Aug-Nov 2009, 4-part series) and Demystifying CMC Regulatory Strategy (Sept 2011-Mar 2012, 4-part series)).
About The Author
John Geigert is President of BioPharmaceutical Quality Solutions, which specializes in providing CMC regulatory strategy consulting for the biopharmaceutical and biologic industry. Dr. Geigert has over 35 years of CMC industrial experience and leadership in the biopharmaceutical industry. Dr. Geigert has served on the PDA Board of Directors, co-chaired the PDA Biotech Advisory Board and served as an expert member of the USP Biotechnology Committee. Dr. Geigert has written extensively for the Regulatory Affairs Professional Society (RAPS) Focus (What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products (Aug-Nov 2009, 4-part series) and Demystifying CMC Regulatory Strategy (Sept 2011-Mar 2012, 4-part series)).
Caracteristici
Highlights the challenges facing quality assurance/quality control (QA/QC) in today's biopharmaceutical environment
Presents the strategic importance and value generated by QA/QC for their involvement in control of manufacturing
Revised 2nd Edition is broadened to include biopharmaceuticals (biotech drugs) and other biologics (vaccines, cell therapy, plasma-derived proteins, etc.)
Includes supplementary material: sn.pub/extras
Presents the strategic importance and value generated by QA/QC for their involvement in control of manufacturing
Revised 2nd Edition is broadened to include biopharmaceuticals (biotech drugs) and other biologics (vaccines, cell therapy, plasma-derived proteins, etc.)
Includes supplementary material: sn.pub/extras
Descriere
Descriere de la o altă ediție sau format:
"The greater our knowledge increases, the more our ignorance unfolds. " U. S. President John F. Kennedy, speech, Rice University, September 12, 1962 My primary purpose for writing this book was much more than to provide another information source on Chemistry, Manufacturing & Controls (CMC) that would rapidly become out of date. My primary purpose was to provide insight and practical suggestions into a common sense business approach to manage the CMC regulatory compliance requirements for biopharmaceuticals. Such a common sense business approach would need (1) to be applicable for all types of biopharmaceutical products both present and future, (2) to address the needs of a biopharmaceutical manufacturer from the beginning to the end of the clinical development stages and including post market approval, and (3) to be adaptable to the constantly changing CMC regulatory compliance requirements and guidance. Trying to accomplish this task was a humbling experience for this author! In Chapter 1, the CMC regulatory process is explained, the breadth of products included under the umbrella ofbiopharmaceuticals are identified, and the track record for the pharmaceutical and biopharmaceutical industry in meeting CMC regulatory compliance is discussed. In Chapter 2, while there are many CMC commonalities between biopharmaceuticals and chemically-synthesized pharmaceuticals, the significant differences in the way the regulatory agencies handle them are examined and the reasons for why such differences are necessary is discussed. Also, the importance of CMC FDA is stressed.
"The greater our knowledge increases, the more our ignorance unfolds. " U. S. President John F. Kennedy, speech, Rice University, September 12, 1962 My primary purpose for writing this book was much more than to provide another information source on Chemistry, Manufacturing & Controls (CMC) that would rapidly become out of date. My primary purpose was to provide insight and practical suggestions into a common sense business approach to manage the CMC regulatory compliance requirements for biopharmaceuticals. Such a common sense business approach would need (1) to be applicable for all types of biopharmaceutical products both present and future, (2) to address the needs of a biopharmaceutical manufacturer from the beginning to the end of the clinical development stages and including post market approval, and (3) to be adaptable to the constantly changing CMC regulatory compliance requirements and guidance. Trying to accomplish this task was a humbling experience for this author! In Chapter 1, the CMC regulatory process is explained, the breadth of products included under the umbrella ofbiopharmaceuticals are identified, and the track record for the pharmaceutical and biopharmaceutical industry in meeting CMC regulatory compliance is discussed. In Chapter 2, while there are many CMC commonalities between biopharmaceuticals and chemically-synthesized pharmaceuticals, the significant differences in the way the regulatory agencies handle them are examined and the reasons for why such differences are necessary is discussed. Also, the importance of CMC FDA is stressed.